Glucose control

Biomarker1 paper1 finding

Animals1

Interventions

1

Semaglutide

upin mice1Very low certainty

1 study

Semaglutide improves glucose control in mice.
Animalscompared to calorie restrictionfemales
Late-life semaglutide treatment slows ageing and extends lifespan in female mice · Nature · 2 Sep 2026

Semaglutide →

Latest

20

BMJ OpenResearch15 h

Effects of ultra-processed food reduction intervention on postprandial glucose and glycaemic variability in Korean young adults: study protocol for the ULTRA-CGM randomised controlled trial

Diabetes, Metabolic Syndrome and ObesityHumans4 Oct

Identifying Patients with Rapid Progression to Diabetic Retinopathy in Type 2 Diabetes: A Simple Prediction Model for Community Settings

Diabetic retinopathy

NeuroepidemiologyIn silico30 Sep

Trends and Projections of Alzheimer's Disease and Other Dementias in East Asia: Three Decades of Epidemiological Analysis (1990-2023) with Forecasts to 2050

CureusHumans24 Sep

Ethnicity-Specific Thyroid Hormone Sensitivity Indices and Their Association With Metabolic Syndrome in Euthyroid South Asian Adults

Metabolic syndrome

The Journal of Clinical Endocrinology and MetabolismIn silico20 Sep

Quantitative Insights into Tirzepatide and Semaglutide Using Longitudinal Systems Modeling

MetabolismHumans16 Sep

Dose-response associations of whole-body and regional body fat with continuous glucose monitoring-derived glycemic level and glycemic variability: A cross-sectional study of Asian adults without diabetes

NatureAnimals3 Sep

Late-life semaglutide treatment slows ageing and extends lifespan in female mice

Cardiovascular DiabetologyReview27 Aug

Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception

ADA Scientific Sessions 2026 AbstractHumans6 Jun

Relationship between BMI and Glucose Metrics in CGM Users in App-Enabled Weight Loss Program

ADA Scientific Sessions 2026 AbstractHuman trial6 Jun

Utreglutide (GL0034) Shows Comparable Tolerability and Efficacy with Different Dose Escalation Regimens in Overweight and Obese Adults with Type 2 Diabetes (T2DM)